Detail akcie Mesoblast online

Business Summary: Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Mesoblast Ltd revenues increased from $5.9M to $17.2M. Net loss increased 16% to $102.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in R&D increase from $2.8M to $12.5M (expense), Employee Benefit Expenses increase of 86% to $18.7M (expense).